Trials / Completed
CompletedNCT04050553
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes. It will last about 42 weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2020-02-24
- Primary completion
- 2022-01-25
- Completion
- 2022-01-25
- First posted
- 2019-08-08
- Last updated
- 2024-05-20
- Results posted
- 2024-05-20
Locations
1 site across 1 country: Austria
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04050553. Inclusion in this directory is not an endorsement.